Burnaby firm partners with pharma Merck to research oral COVID-19 vaccine - Business News castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.
COVID-19 swab in lab Photo: Getty Images
A Burnaby biotech company is partnering with a global pharmaceutical giant on research into advancing delivery of oral vaccines, including for COVID-19.
Symvivo Corporation, a clinical-stage biotechnology company that has a proprietary bacTRL gene delivery platform, announced Tuesday that it has entered into a research collaboration with Merck Sharp and Dohme Corp. Under the terms of the agreement, Merck receives an option to take an exclusive license to Symvivo’s bacTRL platform technology for use in advancing delivery of oral vaccines.
“We are excited to be collaborating with Merck on this novel program,” said Lloyd Mackenzie, president and COO at Symvivo. “This agreement builds on Symvivo’s efforts to develop the bacTRL platform across a range of diverse and important indications.”